vs
WARRIOR MET COAL, INC.（HCC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是WARRIOR MET COAL, INC.的1.7倍（$772.1M vs $458.6M），WARRIOR MET COAL, INC.净利率更高（15.8% vs 12.7%，领先3.0%），WARRIOR MET COAL, INC.同比增速更快（52.1% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 7.5%）
Warrior Met Coal（股票代码HCC）是总部位于美国的矿业企业，主营高品质冶金煤的开采与供应，其产品是钢铁制造的核心原材料，主要服务北美、欧洲、亚洲地区的钢铁生产商及工业客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HCC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$458.6M
营收增速更快
HCC
高出46.2%
5.9%
净利率更高
HCC
高出3.0%
12.7%
两年增速更快
RVTY
近两年复合增速
7.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $458.6M | $772.1M |
| 净利润 | $72.3M | $98.4M |
| 毛利率 | 36.7% | — |
| 营业利润率 | 17.3% | 14.5% |
| 净利率 | 15.8% | 12.7% |
| 营收同比 | 52.1% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $1.37 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCCRVTY
| Q1 26 | $458.6M | — | ||
| Q4 25 | $384.0M | $772.1M | ||
| Q3 25 | $328.6M | $698.9M | ||
| Q2 25 | $297.5M | $720.3M | ||
| Q1 25 | $299.9M | $664.8M | ||
| Q4 24 | $297.5M | $729.4M | ||
| Q3 24 | $327.7M | $684.0M | ||
| Q2 24 | $396.5M | $691.7M |
净利润HCCRVTY
| Q1 26 | $72.3M | — | ||
| Q4 25 | $23.0M | $98.4M | ||
| Q3 25 | $36.6M | $46.7M | ||
| Q2 25 | $5.6M | $53.9M | ||
| Q1 25 | $-8.2M | $42.2M | ||
| Q4 24 | $1.1M | $94.6M | ||
| Q3 24 | $41.8M | $94.4M | ||
| Q2 24 | $70.7M | $55.4M |
毛利率HCCRVTY
| Q1 26 | 36.7% | — | ||
| Q4 25 | 29.5% | — | ||
| Q3 25 | 27.1% | 53.6% | ||
| Q2 25 | 23.9% | 54.5% | ||
| Q1 25 | 18.1% | 56.5% | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 29.3% | 56.3% | ||
| Q2 24 | 34.1% | 55.7% |
营业利润率HCCRVTY
| Q1 26 | 17.3% | — | ||
| Q4 25 | 9.0% | 14.5% | ||
| Q3 25 | 6.3% | 11.7% | ||
| Q2 25 | 2.6% | 12.6% | ||
| Q1 25 | -5.8% | 10.9% | ||
| Q4 24 | -1.4% | 16.3% | ||
| Q3 24 | 11.9% | 14.3% | ||
| Q2 24 | 17.9% | 12.4% |
净利率HCCRVTY
| Q1 26 | 15.8% | — | ||
| Q4 25 | 6.0% | 12.7% | ||
| Q3 25 | 11.1% | 6.7% | ||
| Q2 25 | 1.9% | 7.5% | ||
| Q1 25 | -2.7% | 6.4% | ||
| Q4 24 | 0.4% | 13.0% | ||
| Q3 24 | 12.7% | 13.8% | ||
| Q2 24 | 17.8% | 8.0% |
每股收益（稀释后）HCCRVTY
| Q1 26 | $1.37 | — | ||
| Q4 25 | $0.43 | $0.86 | ||
| Q3 25 | $0.70 | $0.40 | ||
| Q2 25 | $0.11 | $0.46 | ||
| Q1 25 | $-0.16 | $0.35 | ||
| Q4 24 | $0.02 | $0.77 | ||
| Q3 24 | $0.80 | $0.77 | ||
| Q2 24 | $1.35 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.2M | $919.9M |
| 总债务越低越好 | $154.4M | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $2.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HCCRVTY
| Q1 26 | $233.2M | — | ||
| Q4 25 | $300.0M | $919.9M | ||
| Q3 25 | $336.3M | $931.4M | ||
| Q2 25 | $383.3M | $991.8M | ||
| Q1 25 | $454.9M | $1.1B | ||
| Q4 24 | $491.5M | $1.2B | ||
| Q3 24 | $583.2M | $1.2B | ||
| Q2 24 | $709.0M | $2.0B |
总债务HCCRVTY
| Q1 26 | $154.4M | — | ||
| Q4 25 | $154.3M | — | ||
| Q3 25 | $154.1M | — | ||
| Q2 25 | $153.9M | — | ||
| Q1 25 | $153.8M | — | ||
| Q4 24 | $153.6M | — | ||
| Q3 24 | $153.5M | — | ||
| Q2 24 | $153.3M | — |
股东权益HCCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | $7.3B | ||
| Q3 25 | $2.1B | $7.4B | ||
| Q2 25 | $2.1B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.1B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B |
总资产HCCRVTY
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $12.2B | ||
| Q3 25 | $2.7B | $12.1B | ||
| Q2 25 | $2.6B | $12.4B | ||
| Q1 25 | $2.6B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.6B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B |
负债/权益比HCCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.07× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流HCCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $76.1M | $182.0M | ||
| Q3 25 | $104.7M | $138.5M | ||
| Q2 25 | $37.5M | $134.3M | ||
| Q1 25 | $10.9M | $128.2M | ||
| Q4 24 | $54.2M | $174.2M | ||
| Q3 24 | $62.2M | $147.9M | ||
| Q2 24 | $147.0M | $158.6M |
自由现金流HCCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率HCCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度HCCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率HCCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.31× | 1.85× | ||
| Q3 25 | 2.86× | 2.97× | ||
| Q2 25 | 6.70× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 47.68× | 1.84× | ||
| Q3 24 | 1.49× | 1.57× | ||
| Q2 24 | 2.08× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
